Cue Biopharma Files 2023 Annual Report on Form 10-K

TL;DR

<b>Cue Biopharma, Inc. has filed its annual report detailing its 2023 financial performance and corporate information.</b>

AI Summary

Cue Biopharma, Inc. (CUE) filed a Annual Report (10-K) with the SEC on March 28, 2024. Cue Biopharma, Inc. filed its 2023 Form 10-K on March 28, 2024. The filing covers the fiscal year ending December 31, 2023. The company was formerly known as Imagen Biopharma, Inc. and changed its name on June 17, 2015. Cue Biopharma is incorporated in Delaware and headquartered in Boston, MA. The company operates in the Pharmaceutical Preparations industry (SIC 2834).

Why It Matters

For investors and stakeholders tracking Cue Biopharma, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Cue Biopharma's financial health, operational activities, and strategic direction for the fiscal year 2023, which is crucial for investors to assess the company's current standing and future prospects. Understanding the details within this filing is essential for stakeholders to evaluate the company's progress in its drug development pipeline, its financial stability, and any potential risks or opportunities it faces in the competitive biopharmaceutical market.

Risk Assessment

Risk Level: medium — Cue Biopharma, Inc. shows moderate risk based on this filing. The company's financial performance and operational status are detailed in this 10-K, which is a standard disclosure for public companies. However, specific financial figures and growth metrics are not provided in the initial filing header, requiring a deeper dive into the document for a full assessment.

Analyst Insight

Review the full 10-K filing to analyze Cue Biopharma's financial statements, revenue streams, R&D expenditures, and any disclosed forward-looking statements to understand its current operational status and future growth potential.

Key Numbers

• 20231231 — Fiscal Year End (Conformed period of report)
• 20240328 — Filing Date (Filed as of date)
• 001-38327 — SEC File Number (SEC file number)
• 473324577 — IRS Number (IRS number)
• 617-949-2680 — Business Phone (Business phone number)
• 02135 — ZIP Code (Business address ZIP code)

Key Players & Entities

• Cue Biopharma, Inc. (company) — Filer name
• Imagen Biopharma, Inc. (company) — Former company name
• Boston (company) — Business and mailing address city
• DE (company) — State of incorporation
• 20231231 (date) — Conformed period of report
• 20240328 (date) — Filed as of date
• 0000950170-24-038059 (other) — Accession number
• 2834 (other) — Standard Industrial Classification (Pharmaceutical Preparations)

FAQ

Key Dates

• 2024-03-28: 10-K Filing — Annual report filed for the fiscal year ending 2023-12-31.
• 2015-06-17: Name Change — Company formerly known as Imagen Biopharma, Inc.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market
• $3.65 — rant's common stock on June 30, 2023 of $3.65 per share). As of March 25, 2024, the

Filing Documents

• cue-20231231.htm (10-K) — 2571KB
• cue-ex4_2.htm (EX-4.2) — 30KB
• cue-ex10_17.htm (EX-10.17) — 22KB
• cue-ex10_38.htm (EX-10.38) — 27KB
• cue-ex21_1.htm (EX-21.1) — 8KB
• cue-ex23_1.htm (EX-23.1) — 5KB
• cue-ex31_1.htm (EX-31.1) — 13KB
• cue-ex31_2.htm (EX-31.2) — 13KB
• cue-ex32_1.htm (EX-32.1) — 10KB
• cue-ex97_1.htm (EX-97.1) — 25KB
• img77049880_0.jpg (GRAPHIC) — 28KB
• img77049880_1.jpg (GRAPHIC) — 77KB
• img77049880_2.jpg (GRAPHIC) — 55KB
• img77049880_3.jpg (GRAPHIC) — 183KB
• img77049880_4.jpg (GRAPHIC) — 21KB
• img77049880_5.jpg (GRAPHIC) — 184KB
• img77049880_6.jpg (GRAPHIC) — 36KB
• img77049880_7.jpg (GRAPHIC) — 27KB
• img77049880_8.jpg (GRAPHIC) — 19KB
• img77049880_9.jpg (GRAPHIC) — 31KB
• img77049880_10.jpg (GRAPHIC) — 59KB
• img77049880_11.jpg (GRAPHIC) — 19KB
• img77049880_12.jpg (GRAPHIC) — 19KB
• img77049880_13.jpg (GRAPHIC) — 44KB
• img77049880_14.jpg (GRAPHIC) — 92KB
• 0000950170-24-038059.txt (&nbsp;) — 12006KB
• cue-20231231.xsd (EX-101.SCH) — 1542KB
• cue-20231231_htm.xml (XML) — 1262KB

Business

Business 4 Item 1A.

Risk Factors

Risk Factors 48 Item 1B. Unresolved Staff Comments 89 Item 1C. Cybersecurity 89 Item 2.

Properties

Properties 90 Item 3.

Legal Proceedings

Legal Proceedings 90 Item 4. Mine Safety Disclosures 90 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 91 Item 6. [Reserved] 91 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 92 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 105 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 105 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 105 Item 9A.

Controls and Procedures

Controls and Procedures 106 Item 9B. Other Information 106 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 106 PART III Item 10. Directors, Executive Officers and Corporate Governance 107 Item 11.

Executive Compensation

Executive Compensation 107 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters 107 Item 13. Certain Relationships and Related Transactions, and Director Independence 107 Item 14. Principal Accountant Fees and Services 107 PART IV Item 15. Exhibits and Financial Statement Schedules 109 Item 16. Form 10-K Summary 112 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Annual Report on Form 10-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely" or other comparable terms. All statements, other than statements of historical fact, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about: the initiation, timing, progress and results of our ongoing and planned preclinical studies and clinical trials and our research and development programs; our estimates regarding expenses, future revenue, capital requirements and need for additional financing; our expectations regarding our ability to fund our projected operating requirements with our existing cash resources and the period in which we expect that such cash resources will enable us to fund such operating requirements; our plans to develop our drug product

Business

Item 1. Business Overview We are a clinical-stage biopharmaceutical company engineering a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Our vision is to translate nature's signals, or "cues", into protein therapeutics by generating a new class of T cell engagers for selective modulation of disease specific T cells. We believe our proprietary Immuno-STAT ( Selective Targeting and Alteration of T Cells ) platform, as described below, will enable us to enhance the potential of the patient's own immune system to restore health while avoiding the deleterious side effects of broad immune activation, in the case of cancer, and broad immune suppression, in the case of autoimmune disease. Our selective immune modulation approach may be deployed for treating two of the major diseases causing debilitating human suffering and mortality, namely cancer and autoimmune disease. Susceptibility to cancers is likely due to inadequate immunity against aberrant cancer cells, and inversely, autoimmune disease is due to excessive immune activation against self-tissue. Cancer and autoimmune disease are major areas of disease that affect large populations across the globe and shorten the life expectancy of those afflicted. There are approximately 20 million new cancer diagnoses worldwide each year with approximately 2 million in the United States, or U.S., alone. Of these new cases, approximately 50% will progress to recurrent metastatic disease ultimately resulting in death. In addition, approximately 4% of the world's population is diagnosed with an autoimmune disease resulting in approximately 24 million cases in the U.S. Recognizing that T cells, as the heavy artillery of the immune system, are regulated with a highly selective "command and control" instruction process through interactions with the antigen-presenting cells, we have engineered the Immuno-STAT platform to emulate thi

View Full Filing

View this 10-K filing on SEC EDGAR